Immune-related adverse events of immune checkpoint inhibitors: a review

Frontiers in Immunology

Immunology

Liuyun Wu¹  Lian Li¹  Qinan Yin¹  Lizhu Han¹  Yuan Bian¹  Xingyue Zheng¹  Lan Bai¹  Rongsheng Tong¹ 

[1] Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China;Personalized Drug Therapy Key Laboratory of Sichuan Province, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China;

关键词: immune checkpoint inhibitors;    immune-related adverse events;    epidemiology;    mechanism;    management;   

DOI  :  10.3389/fimmu.2023.1167975

 received in 2023-02-24, accepted in 2023-05-15,  发布年份 2023

来源: Frontiers

【 摘 要 】

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has entered a new era, and the response rate and survival rate of many cancers have also been improved. Despite the success of immune checkpoint inhibitors, resistance limits the number of patients who can achieve a lasting response, and immune-related adverse events complicate treatment. The mechanism of immune-related adverse events (irAEs) is unclear. We summarize and discuss the mechanisms of action of immune checkpoint inhibitors, the different types of immune-related adverse events and their possible mechanisms, and describe possible strategies and targets for prevention and therapeutic interventions to mitigate them.

【 授权许可】

Unknown   
Copyright © 2023 Yin, Wu, Han, Zheng, Tong, Li, Bai and Bian